The April 2006 issue of
Contract Pharma
is available now!
Registration for Exhibitors and Attendees is available online
Looking for a contract service provider? Try our online Contract Services Directory
|
- Breaking News
- HGS Gains Cash with Facilities Transactions
Human Genome Sciences, Inc. (HGS) has signed a $425 million definitive agreement with BioMed Realty Trust, Inc. for the sale... » Read More
- Biogen Idec To Buy Conforma
Biogen Idec has signed a definitive merger agreement for the acquisition of Conforma Therapeutics. Conforma is focused on... » Read More
- Executive Moves: AAIPharma
AAIPharma, Inc. has appointed John M. Hall, Ph.D. to the position of president of European operations. With more than 30... » Read More
- Chemokine Achieves Milestone with Cancer Drug
Chemokine Therapeutics has started patient dosing in a Phase Ib/II trial using CTCE-9908, the company's lead anti-cancer product. This trial represents the first... » Read More
- DSM Integrates Manufacturing Businesses
DSM Pharmaceutical Products has integrated its custom manufacturing service offerings for pharmaceutical and biopharmaceutical... » Read More
- Features:
- Parenteral Manufacturing
A sector driven by solid, veteran performers braces for growth ÷ but how much and from where?
by Tom Spurgeon
The market outlook for parenteral contract manufacturing finds itself caught between two versions of the immediate future. One scenario looks at new cancer drugs and the considerable number of biologics in late-stage testing and predicts a parade of new products, the equivalent of on-the-red-carpet attention and spiraling, higher demand. The other, frequently described by the CMOs themselves, sees steady increases over the next few... » Read entire article
- Development of A Bio-Derived Drug
Using a risk-based approach from discovery to proof of concept
by James Murtagh
Risk management is a way to take a proactive approach to building quality into a development program. This article is meant to provide an overview and an example (from the collective experience of a contract services provider) of a risk-based approach to developing a biologically derived entity as a therapeutic agent. Development of any therapeutic agent from lead identification to proof of concept in man is a time-consumin... » Read entire article
- Outsourcing Bio-Production to Asia
Are attitudes changing?
by Sandra Fox
Although production of chemical-based pharmaceuticals has long been outsourced to contract manufacturers in lower-cost Asian regions, biopharmaceutical production is still primarily done in North America and Western Europe. Most biomanufacturing directors at pharmaceutical and biotechnology companies typically state that they have no current intention of outsourcing production of biologics to Asian regions. However, the tide is beginning... » Read entire article
- Site Selection Criteria
It's all about location - but what makes a location good?
by Gil Y. Roth
Choosing a location for a Pharma or Biopharma manufacturing facility isn’t for the faint of heart. Regions and municipalities develop generous packages to bring companies in, but the decision isn’t always based on dollars and cents. While it’s true that, “The greater the scale, the greater the investment,” smaller firms have even more to lose from a wrong decision, and must go through the process as carefull... » Read entire article
|
 |
